The European Medicines Agency's negative review of Vimpat's use in diabetic neuropathic pain has prompted UCB SA to drop its EU application for the expanded use of the epilepsy treatment. A UCB spokeswoman said the Belgian drugmaker plans to conduct an additional clinical study "to further substantiate the magnitude" of Vimpat's effects in patients with diabetic neuropathic pain.

Full Story:

Related Summaries